[Nitrate tolerance].
Nitrate tolerance is defined as an attenuation or even loss of hemodynamic and anti-ischemic effects during continuous nitrate medication. The blunted response may be due to the development of pseudotolerance and true pharmacologic tolerance. Pseudotolerance is the result of volume and salt retention, as well as the stimulation of counter-regulatory mechanisms which may alter the baseline hemodynamics of a patient during nitrate therapy. Far less important are changes in nitrate pharmacokinetics. True pharmacological tolerance may also be of practical importance. Diminished uptake of nitrates into the vascular smooth muscle cell, a decrease in intracellular SH groups, inhibition of the guanylate-cyclase, and stimulation of a specific phosphodiesterase may result in a decrease of cyclic GMP formation and hence to a decrease in nitrate induced vasodilatation. Tolerance development may be prevented by intermittent nitrate administration providing intervals with low plasma and tissue nitrate levels. In consequence, nitrates should be used predominantly for treatment of ischemic episodes, but 24-hour anti-ischemic action for the prevention of ischemia can be better achieved by treatment with a beta-blocker and/or a calcium antagonist. Nitrates should be added in times of maximum susceptibility to ischemia, while allowing nitrate levels to fall at other times.
Bertel
O
O
Medizinische Klinik Stadtspital Triemli, Zürich.
D003327:Coronary Disease / Q000188:drug therapy; D006152:Cyclic GMP / Q000096:biosynthesis; D004361:Drug Tolerance; D004789:Enzyme Activation / Q000187:drug effects; D006162:Guanylate Cyclase / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D009566:Nitrates / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D014882:Water-Electrolyte Balance / Q000187:drug effects
D009566:Nitrates; D006162:Guanylate Cyclase; D006152:Cyclic GMP
Nitrattoleranz.